Most Recent Episode
MRD diagnostics and mantle cell lymphoma

MRD diagnostics and mantle cell lymphoma

Prof Georg Hess (University Medical Center Mainz, Mainz, Germany) chairs an expert discussion at the Mantle Cell Lymphoma (MCL) Current Treatment Practices Meeting in Brussels, Belgium, for ecancerTV.
Time: 0:01
Prof Georg Hess (University Medical Center Mainz, Mainz, Germany) chairs an expert discussion at the Mantle Cell Lymphoma (MCL) Current Treatment Practices Meeting in Brussels, Belgium, for ecancerTV.
He is joined by Prof Christian Buske (University of Ulm, Ulm, Germany), Prof Steven Le Gouill (University Hospital of Nantes, Nantes, France) and Prof Eva Kimby (Karolinska Institute, Stockholm, Sweden).
In the second part of the discussion the panel members talk about the use of minimal residual disease (MRD) diagnostics and how they may help with the diagnosis of indolent lymphomas and perhaps the earlier treatment of patients.
Episode ID: 1000356083638
GUID: CobaltPublic69/v4/64/8c/2b/648c2bf7-7325-ff61-4e8b-7c4a69d6fbab/328-3896058414529826711-MCL_CTP_RT_PT1.mp4
Release Date: 01/11/2015, 15:11:00

Description

Prof Georg Hess (University Medical Center Mainz, Mainz, Germany) chairs an expert discussion at the Mantle Cell Lymphoma (MCL) Current Treatment Practices Meeting in Brussels, Belgium, for ecancertv.
He is joined by Prof Christian Buske (University of Ulm, Ulm, Germany), Prof Steven Le Gouill (University Hospital of Nantes, Nantes, France) and Prof Eva Kimby (Karolinska Institute, Stockholm, Sweden).
During the discussion the experts talk about current treatment algorithms for a variety of patients with MCL, starting with younger patients and those eligible for haematopoietic stem cell transplantation (HSCT), and how recent trial data may help to improve upon current standards of care. This includes discussion around maintenance rituximab and the potential for using the Bruton's tyrosine kinase inhibitor ibrutinib.
They also overview what to do in the case of older and more frail patients who may not be eligible for HSCT and may be less able to tolerate more intensive treatment approaches.
The panel members also give their thoughts on the use of newer targeted agents and the practicalities of using these based on current knowledge in patients with MCL.

Feed URL

Customer Reviews

No Entry